News

Tentative Approval for Generic Lumateperone capsules

Dr. Reddy’s Wins Big at “Express Pharma Excellence Awards 2025”

In a remarkable stride for innovation and speed, Dr. Reddy’s Laboratories has received Tentative Approval for Generic Lumateperone capsules a milestone that marks a new benchmark in small molecule development. Filed on NCE-1, this submission reflects our commitment to strategic excellence and scientific precision. Lumateperone completed DMF adequacy and received Tentative Approval in just 20 months, one of the fastest timelines in recent years for a small molecule. This is more than just a regulatory milestone. It’s a testament to our agility, collaboration, and relentless pursuit of quality. Congratulations to everyone who made this possible. For queries contact us at api@drreddys.com

Email us: api@drreddys.com
+91 40 49002253

Contact Us

Please fill in the following form and we'll get back to you shortly.

* I agree and accept the Privacy Policy and Terms of Use of this website.

Email us: api@drreddys.com | +91 40 49002222

Disclaimer

No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.